Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the ...

Biocon plans to list its biosimilars business by March 2026, targeting a double-digit market share in the U.S. with five new ...

Peter Bains, Group CEO of Biocon, talks about India's budget, and the impact of its plans to cut or remove duties on ...

The share price of Biocon has fallen more than 5% in the last five trading days. (Image: Freepik) The share price of Biocon ...

Adjusting for these factors, Biocon’s Q3 FY25 revenue saw a 10 per cent year-on-year growth. The company’s net research and ...

Shares of Biocon Ltd closed slightly higher at ₹357.15 on the BSE today, up 0.44% or ₹1.55, ahead of the earnings ...

Hyderabad: Biopharma major Biocon plans to introduce five new biosimilars in the United States in the new fiscal year, ...

Biocon share price gained 2.61 per cent at Rs 398 a piece on the BSE in Thursday’s intraday trade. This came after the ...

Biocon's board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2 ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

HYDERABAD, Jan 30 (Reuters) - Indian biopharma company Biocon (BION.NS), opens new tab reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period ...